ArticleBMC nephrology2023

A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.

Thomas Ward et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.